Calcium methoxide

• 分子结构分类: 有机化合物 - 有机盐 - 有机金属盐
• 英文名称: Calcium methoxide
• 英文别名: calcium;methanolate
• 化学式: C2H6CaO2
• mdl: MFCD00058816
• 分子量: 102.15
• InChiKey: AMJQWGIYCROUQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.52
• 重原子数：
  5
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 Calcium methoxide 生成 甲酸甲酯
  参考文献：
  名称：

  SAVITSKIJ YU. V.; CHERNYAK B. I., BECTH. LVOV. POLITEXN. IN-TA, 1980, HO 139, 61-64

  摘要：

  DOI：
• 作为产物：
  描述：

  氢氧化钙 生成 Calcium methoxide
  参考文献：
  名称：

  WITHUM, JEFFREY A.;YOON, HEEYOUNG, ENVIRON. SCI. AND TECHNOL., 23,(1989) N, C. 821-827

  摘要：

  DOI：

文献信息

• Method of manufacturing an amorphous form of the hemi-calcium salt of (3r, 5r) 7-3-phenly-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (actorvastatin)
  申请人：Radl Stanislav

  公开号：US20050131055A1

  公开（公告）日：2005-06-16

  A method of manufacturing an amorphous form of the hemi-calcium salt of (3R, 5R) 7-[3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid of formula (I), in which (3R, 5R) 7-[3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid or its salt with a cation M + wherein M 30 is either a cation of an alkali metal or an ammonium cation of formula R n N (+) H (4−n) wherein R is lower C 1 -C 5 alkyl, n may reach values ranging between 0 and 3, is, without isolating the intermediate in the form of the hemi-calcium salt or of another salt, acid or lactone, converted, in a solution, by the treatment with the calcium salt or calcium hydroxide, or a calcium C 1 -C 5 alcoholate, to the hemi-calcium salt, and the latter is precipitated with a C 1 -C 5 hydrocarbon or dialkylether of formula R 1 OR 2 , wherein each of R 1 and R 2 is a C 1 -C 5 alkyl group. The starting acid or its salt is prepared starting from (3R, 5R) tert-butyl (6-2-[3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl]-ethyl}-2,2-dimethyl-[1,3]dioxane-4-yl)acetate of formula II.

  一种制备（3R,5R）7-[3-苯基-4-苯基氨甲酰基-2-(4-氟苯基)-5-异丙基吡咯-1-基]-3,5-二羟基庚酸的半钙盐非晶态的方法，其中（3R,5R）7-[3-苯基-4-苯基氨甲酰基-2-(4-氟苯基)-5-异丙基吡咯-1-基]-3,5-二羟基庚酸或其与M+阳离子形成的盐，其中M30为碱金属阳离子或公式RnN(+)H(4−n)的铵阳离子，其中R为较低的C1-C5烷基，n的值在0到3之间，不需要将中间体以半钙盐或其他盐、酸或内酯的形式分离，通过处理钙盐或氢氧化钙或C1-C5醇钙盐的溶液，将其转化为半钙盐，并用公式R1OR2的C1-C5烃或双烷基醚沉淀。起始酸或其盐是从公式II的（3R,5R）叔丁基(6-2-[3-苯基-4-苯基氨甲酰基-2-(4-氟苯基)-5-异丙基吡咯-1-基]-乙基}-2,2-二甲基-[1,3]二氧杂环戊烷-4-基)醋酸酯开始制备的。
• Method of forming patterned oxide superconducting films
  申请人：AMP Incorporated

  公开号：US05021398A1

  公开（公告）日：1991-06-04

  The present invention describes a method to produce a patterned superconducting solid preferably as a thin film. Unsaturated organic acid metal salts of suitable metals are dissolved in an organic solvent, mixed thoroughly and cast as a film on a substrate. The concentration of these organic carboxylate metal salts is adjusted such that a superconducting metal oxide ratio is obtained upon pyrolysis at temperatures up to 1000.degree. C. with subsequent slow cooling. A pattern (mask) is placed over the film and the film is irradiated to polymerize and crosslink the exposed portions. The unpolymerized and uncrosslinked portions are removed usually by using selective solvents or solvent mixtures. The solid remaining is heated in oxygen or air to about 1000.degree. C., which removes the organic portions and leaves metal oxide residue. The metal oxides are then cooled slowly and annealed to produce the patterned metal oxide superconducting materials. The articles of manufacture produced are useful in fabricating devices requiring superconducting thin films in addition to other uses.

  本发明描述了一种制备图案超导固体的方法，最好是作为薄膜。将合适金属的不饱和有机酸金属盐溶解在有机溶剂中，充分混合并铸成薄膜放在基板上。调整这些有机羧酸金属盐的浓度，使在高达1000°C的热解过程中获得超导金属氧化物比例，随后缓慢冷却。将图案（掩膜）放在薄膜上，并照射薄膜以使暴露部分聚合和交联。通常使用选择性溶剂或溶剂混合物去除未聚合和未交联的部分。剩余的固体在氧气或空气中加热到约1000°C，这将去除有机部分并留下金属氧化物残留物。然后缓慢冷却和退火以产生图案的金属氧化物超导材料。制造出的制品在制造需要超导薄膜的设备以及其他用途方面非常有用。
• Preparation of calcium pantothenate
  申请人：——

  公开号：US04052451A1

  公开（公告）日：1977-10-04

  Beta-amino propionitrile is hydrolyzed with potassium hydroxide to produce potassium beta alanate, which, upon acidification produces free beta alanine with some potassium sulfate precipitate. The beta alanine solution with residual potassium sulfate is concentrated under vacuum to a thick syrup, shocked with an excess of a selected alcohol to produce a solid mass of beta alanine with the remaining theoretical potassium sulfate. The solid product is converted to calcium beta alanate under anhydrous conditions for reaction with racemic pantoyl lactone to form pure calcium pantothenate and allowing the entrained potassium sulfate to settle out. Contrary to expectations, under these conditions there was no double displacement and the presence of potassium sulfate did not interfere with the reaction.

  Beta-氨基丙腈与氢氧化钾水解，产生β-丙氨酸钾盐，酸化后产生游离的β-丙氨酸和一些硫酸钾沉淀。剩余的硫酸钾混合β-丙氨酸溶液在真空下浓缩成浓稠的糖浆，然后用过量的选择性醇突然加热，使得β-丙氨酸与理论上剩余的硫酸钾形成固体。在无水条件下，将固体产物转化为β-丙氨酸钙盐，与外消旋泛酰乳内酯反应，形成纯的泛酸钙，同时使带入的硫酸钾沉淀。与预期相反，在这些条件下没有发生双置换反应，硫酸钾的存在也没有干扰反应。
• Method of manufacturing an amorphous form of the hemi-calcium salt of (3R,5R) 7-3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yll-3, 5-dihydroxyheptanoic acid (actorvastatin)
  申请人：Zentiva A. S.

  公开号：US07208608B2

  公开（公告）日：2007-04-24

  A method of manufacturing an amorphous form of the hemi-calcium salt of (3R, 5R) 7-[3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid of formula (I), in which (3R, 5R) 7-[3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid or its salt with a cation M+ wherein M30 is either a cation of an alkali metal or an ammonium cation of formula RnN(+)H(4−n) wherein R is lower C1–C5 alkyl, n may reach values ranging between 0 and 3, is, without isolating the intermediate in the form of the hemi-calcium salt or of another salt, acid or lactone, converted, in a solution, by the treatment with the calcium salt or calcium hydroxide, or a calcium C1–C5 alcoholate, to the hemi-calcium salt, and the latter is precipitated with a C1–C5hydrocarbon or dialkylether of formula R1OR2, wherein each of R1 and R2 is a C1–C5 alkyl group. The starting acid or its salt is prepared starting from (3R, 5R) tert-butyl (6-2-[3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl]-ethyl}-2,2-dimethyl-[1,3]dioxane-4-yl) acetate of formula II.

  一种制备(3R, 5R) 7-[3-苯基-4-苯基氨基甲酰基-2-(4-氟苯基)-5-异丙基吡咯-1-基]-3,5-二羟基庚酸半钙盐的非晶态形式的方法，其中(3R, 5R) 7-[3-苯基-4-苯基氨基甲酰基-2-(4-氟苯基)-5-异丙基吡咯-1-基]-3,5-二羟基庚酸或其与阳离子M+的盐，其中M+是碱金属的阳离子或公式RnN(+)H(4−n)的铵阳离子，其中R是较低的C1-C5烷基，n的值可以在0和3之间，通过在溶液中用钙盐或钙氢氧化物或钙C1-C5醇盐处理而不隔离半钙盐或其他盐，酸或内酯的中间体，将其转化为半钙盐，并用公式R1OR2的C1-C5烃或二烷基醚沉淀后得到该半钙盐。起始酸或其盐是从公式II的(3R, 5R)叔丁基(6-2-[3-苯基-4-苯基氨基甲酰基-2-(4-氟苯基)-5-异丙基吡咯-1-基]-乙基}-2,2-二甲基-[1,3]二噁烷-4-基) 醋酸酯开始制备的。
• STORK, G.;SHINER, C. S.;WINKLER, J. D., J. AMER. CHEM. SOC., 1982, 104, N 1, 310-312
  作者：STORK, G.、SHINER, C. S.、WINKLER, J. D.

  DOI：——

  日期：——